XML 75 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Shareholders' Equity (Deficit) - USD ($)
shares in Thousands, $ in Thousands
Total
April 2027 Notes
October 2023 Notes
At-the-market offering program
Public offering
Cumulative Effect, Period of Adoption, Adjustment
Ordinary shares
Ordinary shares
April 2027 Notes
Ordinary shares
October 2023 Notes
Ordinary shares
At-the-market offering program
Ordinary shares
Public offering
Preferred shares
Preferred shares
Public offering
Additional paid-in capital
Additional paid-in capital
April 2027 Notes
Additional paid-in capital
October 2023 Notes
Additional paid-in capital
At-the-market offering program
Additional paid-in capital
Public offering
Additional paid-in capital
Cumulative Effect, Period of Adoption, Adjustment
Accumulated deficit
Accumulated deficit
Cumulative Effect, Period of Adoption, Adjustment
Accumulated other comprehensive loss
Beginning balance (in shares) at Dec. 31, 2020             58,396         488                    
Beginning balance at Dec. 31, 2020 $ 162,266         $ (12,939) $ 583         $ 5   $ 566,916         $ (26,699) $ (384,187) $ 13,760 $ (21,051)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                            
Net loss (77,329)                                     (77,329)    
Other comprehensive income (loss) (2,889)                                         (2,889)
Exercise of stock options (in shares)             48                              
Exercise of stock options 169           $ 1             168                
Vesting of restricted shares (in shares)             159                              
Vesting of restricted shares 0           $ 2             (2)                
Employee share purchase plan share issuance (in shares)             17                              
Employee share purchase plan share issuance 94                         94                
Share-based compensation expense 8,872                         8,872                
Ending balance (in shares) at Dec. 31, 2021             58,620         488                    
Ending balance at Dec. 31, 2021 78,244           $ 586         $ 5   549,349         $ (26,699) (447,756) $ 13,760 (23,940)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                            
Net loss (137,464)                                     (137,464)    
Other comprehensive income (loss) (2,401)                                         (2,401)
Change in fair value of October 2023 Notes conversion feature 5,508                         5,508                
Issuance of common stock, net of issuance costs (in shares)                   3,588                        
Issuance of common stock, net of issuance costs       $ 25,318           $ 36             $ 25,282          
Amortization of deferred issuance costs (45)                         (45)                
Exercise of stock options (in shares)             451                              
Exercise of stock options 2,460           $ 4             2,456                
Vesting of restricted shares (in shares)             144                              
Vesting of restricted shares 0           $ 1             (1)                
Employee share purchase plan share issuance (in shares)             75                              
Employee share purchase plan share issuance 222           $ 1             221                
Share-based compensation expense 7,013                         7,013                
Ending balance (in shares) at Dec. 31, 2022             62,878         488                    
Ending balance at Dec. 31, 2022 (21,145)           $ 628         $ 5   589,783           (585,220)   (26,341)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                            
Net loss (160,276)                                     (160,276)    
Other comprehensive income (loss) 3,174                                         3,174
Issuance of common stock, net of issuance costs (in shares)                   1,564 12,205   4,706                  
Issuance of common stock, net of issuance costs       $ 11,913 $ 134,151         $ 16 $ 122   $ 47       $ 11,897 $ 133,982        
Amortization of deferred issuance costs $ (16)                         (16)                
Exchange/Settlement of Notes (in shares)               12,347 408                          
Exchange/Settlement of Notes   $ 101,812 $ 22         $ 123 $ 4           $ 101,689 $ 18            
Exercise of stock options (in shares) 342           343                              
Exercise of stock options $ 2,062           $ 4             2,058                
Vesting of restricted shares (in shares)             33                              
Employee share purchase plan share issuance (in shares)             47                              
Employee share purchase plan share issuance 231           $ 1             230                
Share-based compensation expense 15,811                         15,811                
Ending balance (in shares) at Dec. 31, 2023             89,825         5,194                    
Ending balance at Dec. 31, 2023 $ 87,739           $ 898         $ 52   $ 855,452           $ (745,496)   $ (23,167)